---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031281"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-09-28T11:15:10+00:00"
generated_at: "2026-10-12T13:30:07.687832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals launches IMPAVIDO (miltefosine) in U.S., its 11th commercial rare disease product

## Summary
- U.S. commercial launch of IMPAVIDO (miltefosine) capsules; Eton holds exclusive U.S. commercialization rights for the antileishmanial therapy.
- IMPAVIDO is indicated for visceral, cutaneous and mucosal leishmaniasis in adults and adolescents at least 12 years old weighing 30 kg (66 lbs) or more.
- Eton Cares patient support includes $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
- Distribution via Anovo Specialty Pharmacy (e-prescribe Anovo #5 Memphis; referral fax 855-813-2039; line 877-469-4078); hospital consignment stocking and emergency access pathway.
- Eton now lists eleven commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE and IMPAVIDO, plus five late-stage candidates (AMGLIDIA, ASN-001, ET-700, ET-800, ZENEO).

## SEC filing metadata
- accession: 0001437749-26-031281
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-09-28T11:15:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/0001437749-26-031281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/eton20260923c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031281
- JSON: https://secwatch.observer/filing/0001437749-26-031281.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.